Zacks Research Weighs in on Integra LifeSciences Holdings Co.’s Q3 2022 Earnings (NASDAQ:IART)

Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) – Research analysts at Zacks Research dropped their Q3 2022 EPS estimates for Integra LifeSciences in a research report issued on Monday, September 19th. Zacks Research analyst U. Biswas now forecasts that the life sciences company will post earnings per share of $0.79 for the quarter, down from their prior forecast of $0.80. The consensus estimate for Integra LifeSciences’ current full-year earnings is $3.15 per share. Zacks Research also issued estimates for Integra LifeSciences’ Q4 2022 earnings at $0.88 EPS, FY2022 earnings at $3.24 EPS, Q1 2023 earnings at $0.79 EPS, Q2 2023 earnings at $0.90 EPS, Q3 2023 earnings at $0.95 EPS, FY2023 earnings at $3.57 EPS, Q1 2024 earnings at $0.70 EPS and FY2024 earnings at $3.71 EPS.

IART has been the topic of a number of other reports. TheStreet downgraded shares of Integra LifeSciences from a “b-” rating to a “c+” rating in a report on Friday, July 8th. Piper Sandler lowered their price objective on shares of Integra LifeSciences from $55.00 to $50.00 in a report on Wednesday, August 24th. Truist Financial decreased their target price on shares of Integra LifeSciences from $70.00 to $56.00 and set a “hold” rating for the company in a research note on Wednesday, July 20th. Finally, Morgan Stanley decreased their target price on shares of Integra LifeSciences from $59.00 to $58.00 and set an “equal weight” rating for the company in a research note on Thursday, August 25th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Integra LifeSciences presently has a consensus rating of “Hold” and a consensus target price of $65.43.

Integra LifeSciences Price Performance

NASDAQ IART opened at $44.59 on Wednesday. The company has a quick ratio of 2.76, a current ratio of 3.85 and a debt-to-equity ratio of 0.90. Integra LifeSciences has a 12-month low of $44.21 and a 12-month high of $74.98. The company has a market capitalization of $3.72 billion, a PE ratio of 22.63, a price-to-earnings-growth ratio of 1.51 and a beta of 1.12. The firm’s 50 day moving average is $52.11 and its 200-day moving average is $57.61.

Institutional Investors Weigh In On Integra LifeSciences

A number of institutional investors have recently modified their holdings of IART. Steward Partners Investment Advisory LLC boosted its position in shares of Integra LifeSciences by 73.7% in the first quarter. Steward Partners Investment Advisory LLC now owns 707 shares of the life sciences company’s stock valued at $45,000 after acquiring an additional 300 shares during the period. First Horizon Advisors Inc. bought a new stake in shares of Integra LifeSciences in the second quarter valued at about $54,000. Aubrey Capital Management Ltd bought a new stake in shares of Integra LifeSciences in the second quarter valued at about $76,000. Covestor Ltd boosted its position in shares of Integra LifeSciences by 63.0% in the first quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock valued at $100,000 after acquiring an additional 602 shares during the period. Finally, Captrust Financial Advisors boosted its position in shares of Integra LifeSciences by 95.0% in the first quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock valued at $129,000 after acquiring an additional 976 shares during the period. Institutional investors own 87.33% of the company’s stock.

Insiders Place Their Bets

In other Integra LifeSciences news, EVP Lisa Evoli sold 1,165 shares of Integra LifeSciences stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $55.81, for a total transaction of $65,018.65. Following the completion of the transaction, the executive vice president now directly owns 17,997 shares of the company’s stock, valued at $1,004,412.57. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Integra LifeSciences news, Director Raymond G. Murphy sold 8,000 shares of Integra LifeSciences stock in a transaction on Friday, August 5th. The shares were sold at an average price of $55.78, for a total transaction of $446,240.00. Following the completion of the transaction, the director now directly owns 40,825 shares of the company’s stock, valued at $2,277,218.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Lisa Evoli sold 1,165 shares of Integra LifeSciences stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $55.81, for a total transaction of $65,018.65. Following the transaction, the executive vice president now directly owns 17,997 shares of the company’s stock, valued at $1,004,412.57. The disclosure for this sale can be found here. Insiders sold a total of 9,602 shares of company stock valued at $536,067 over the last ninety days. 4.20% of the stock is currently owned by company insiders.

Integra LifeSciences Company Profile

(Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

Featured Stories

Earnings History and Estimates for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.